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may have a beneficial effect in reducing the incidence of AD. 5 Accumulating evidence from non-randomized observational studies 6-9 has shown that antihypertensive treatment has prevented a decline in cognitive function or the incidence of dementia. 10 Whether certain antihypertensive agents provide benefits in addition to their blood pressure (BP) lowering effects, such as independently reducing the incidence of AD in general, has been an issue of considerable debate. Observational and experimental research suggest that the renin-angiotensin system (RAS) may be involved in the pathogenesis and progression of AD, but the results from several studies of the relationship between angiotensin-converting enzyme (ACE) inhibitors and the risk of AD were not consistent. 11 -13 According to neuropathological evidence, 12 angiotensinreceptor blockers (ARB) inhibit the AT1 receptor selectively, theoretically preserving ACE production, which may degrade Aβ accumulation in the brain. This has been proposed to have better cognitive outcome than other medications for BP control. Recently, studies in both animals and humans have demonstrated an association between ARB treatment and preservation of cognitive function, with the benefit possibly extending beyond the BP reducing effect. 14 However, the relationship between ARB use and risk of AD has remained undetermined in Asian populations. Keeping this in mind, we set up a largescale, nationwide, population-based cohort to investigate whether the risk of AD is reduced in patients receiving ARB therapy when compared with age-, sex-, and comorbidity-matched controls.
Methods

Database
The National Health Insurance (NHI) program in Taiwan has operated since 1995, enrolling nearly all the inhabitants of Taiwan (21,869,478 beneficiaries among 22,520,776 inhabitants at the end of 2002). Currently, the NHI Research Database at the National Health Research Institutes in Miaoli, Taiwan, manages the complete NHI claims database and has published several dozen extracted data sets for researchers. 15 The National Health Research Institutes has released a cohort data set consisting of 1 million randomly sampled individuals who were alive in 2000, and collected all records on these individuals from 1995 onward. It is one of the largest nationwide population-based databases in the world. These random samples have been confirmed by the National Health Research Institutes to be representative of the Taiwanese population. 16 In this cohort data set, each patient's original identification number has been encrypted to protect privacy. The encrypting procedure is consistent, so the linkage of claims belonging to the same patient is feasible within the data sets. , were also excluded. Thereafter, all hypertensive subjects who fulfilled the inclusion criteria were divided according to the use of ARBs. ARBs were identified and classified by the National Drug Code and the Anatomic Therapeutic Chemical Code, which is an internationally accepted classification system of drugs coordinated by the World Health Organization's Collaborating Center for Drug Statistics method. ARBs included losartan (C09CA01 and C09DA01), valsartan (C09CA03, C09DA03, and C09DB01), irbesartan (C09CA04 and C09DA04), candesartan (C09CA06 and C09DA06), telmisartan (C09CA07 and C09DA07), and olmesartan (C09CA08 and C09DA08). Patients had to have received a prescription for at least 90 pills of ARBs during the observation period.
Study Cohorts
In the comparison cohort, subjects were selected from the aforementioned cohort dataset with newly diagnosed HT and without a prior diagnosis of dementia. After excluding the ARB users, the comparison cohort was selected from the dataset using a propensity score matching method. Propensity matching was used in matching the following characteristics: age, sex, and preexisting (in the year before treatment) comorbidities such as DM (250.xx), coronary artery disease (410.xx-414.xx), and valvular heart disease (394.xx-397.xx). The endpoint of the study included the new occurrence of AD before the end of 2007.
Definition of AD
In order to investigate the association between ARB use and AD, dementia related to ischemic stroke (433.xx-434.xx, 436, 437.1) was excluded and we therefore defined the diagnosis of AD as having the ICD code of either AD (331.0) or senile dementia (290.0, 290.2, 290.20, 290.21, 290.3) without other significant secondary cause of cognitive impairment.
Statistical Analysis
Microsoft SQL Server (Microsoft Corporation, Redmond, WA, USA) was used for data management and computing. Statistical analysis was performed using SPSS version 15.0 (SPSS, Inc, Chicago, IL, USA). All data are expressed as the frequency (percentage) or mean ± SD. Parametric continuous data among 
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the different groups of patients were compared using unpaired Student's t-tests. Categorical data among the different groups were compared using the chi-square test and Yates' correction or Fisher's exact test as appropriate. Survival analysis was assessed using Kaplan-Meier analysis, with significance based on the log-rank test. Multiple regression analysis was carried out using Cox proportional hazards regression analysis. Statistical significance was inferred at a 2-sided P-value <0.05.
Results
A total of 16,426 newly diagnosed hypertensive patients who were administered an ARB and without a previous diagnosis of AD, and 16,485 matched non-exposed controls were identified from the 1,000,000 sampling cohort dataset of the Taiwan NHI database from January 1, 2000 to December 31, 2006 (Figure 1 ). Hypertensive patients with ARB treatment more frequently had a history of congestive heart failure and hyperlipidemia, and more frequently took α-blockers, calcium-channel blockers (CCBs) and thiazides ( Table 2) . Having considered various ARB regimens, it was found that there was no significant difference between ARBs, and all ARBs showed a similar neutral effect in determining the future risk of AD development ( Table 3) . Subsequent analysis of the use of ARBs in subgroups did not show any difference in AD risk between ARB users and non-ARB users (Figure 3) .
Discussion
Although emerging evidence suggests ARB use may decrease the incidence and progression of AD, evidence of the association between ARBs and AD, especially in Asian populations, is still scarce. The current study demonstrated that the risk of developing future AD is not significantly associated with the use of ARB among Asian patients with essential HT. To our knowledge, this is the largest Asian population-based study to investigate the association of ARB exposure with the risk of AD among hypertensive patients in primary care.
Recently, some studies have demonstrated that ARBs might have a neuroprotective property through several biological mechanisms, including a tissue-specific effect toward brain RAS, reducing Aβ deposition in brain tissue, decreasing oxidative stress in cerebral microvessels, and anti-inflammatory effects in the central nervous system. 11,17-20 In 2 large population-based cohort studies from the United Kingdom 21 and United States, 22 ARB use was reported as associated with a lower incidence of AD. However, these neuroprotective benefits of ARB were not observed to be equally clinically effective in randomized clinical trials (RCT). In the studies with a RCT design to evaluate the effect of ARBs on cognitive function, the Study on Cognition and Prognosis in the Elderly (SCOPE) 23 and the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trials, 24 there were no significant differences in the rate of cognitive decline or incidence of AD between the treatment group and the control group. In the SCOPE trial, a total of 4,964 hypertensive patients were recruited and treated with candesartan or placebo (open-label antihypertensive drugs were added to both groups) for a mean follow-up period of 3.7 years. There was no significant difference between the treatment and placebo groups in the Mini Mental State Examination (MMSE) score, incidence of dementia (6.8 vs. 6.3 cases per 1,000 patient-year, P>0.20), or cognitive decline (15.2 vs. 13.5 cases per 1,000 patient-year, P>0.20). In the PRoFESS trial, 20,332 subjects with ischemic stroke were treated with telmisartan or placebo. The rates of cognitive Tables 1,2 . ARB and AD in HT Patients decline on placebo and active treatment were 11% and 11%, respectively (relative risk: 0.95; 95% CI: 0.87-1.05) without significant difference. Recent secondary analysis of the effects of RAS blockade on cognitive function in the doubleblind RCT ONTARGET study and its parallel TRANSCEND trial also showed no clear effects on cognitive outcomes. 25 In ONTARGET, cognitive impairment occurred in 652 (8%) of 7,865 patients treated with ramipril, in 584 (7%) of 7,797 treated with telmisartan, and in 618 (8%) of 7,807 with combination treatment, without significant difference in each of the groups. In TRANSCEND, the incidence of cognitive impairment was 9% in 2,694 participants receiving telmisartan, compared with 9% in 2,689 subjects with placebo [odds ratio (OR) 0.97, 0.81-1.17, P=0.76]. The corresponding data for cognitive decline were 454 (17%) and 412 (16%; OR 1.10, 0.95-1.27, P=0.22). Moreover, meta-analyses also yielded negative results for AD risk reduction with ACE inhibitor/ARB regimens. 26, 27 In a systematic review of 4 double-blind, placebocontrolled RCTs including 15,936 hypertensive subjects, the incidence of dementia indicated no significant difference between treatment and placebo (236/7,767 vs. 259/7,660, OR 0.89, 95% CI 0.74, 1.07), and the change in MMSE did not indicate a benefit from treatment. In a meta-analysis of clinical trials in Japan, CCB-based antihypertensive regimens were found to reduce the risk of dementia more when compared with the controls, and even ACE inhibitor/ARB-based regimens. 28 Our results are consistent with these RCT and meta-analysis conclusions, which showed no convincing evidence that ARBs are beneficial for the primary prevention of AD. Our study has several strengths and limitations. It was a large, nationally representative study of primary care subjects with measurement of comorbidities in both males and females (M/F 53.2/46.8%). The average age of our study cohort was approximately 57.5 years, with a mean follow-up duration of 5.24 years. We used propensity score matching, which has been widely used in control selection in large-sample databases to control the baseline characteristics and comorbidities between 2 groups. In order to study the effect of ARBs on AD, we excluded subjects with dementia or any diagnosis of apparent cerebrovascular disease before the start of antihypertensive treatment. In addition to the negative finding regarding ARB use and AD risk reduction, our data showed that traditional risk factors for dementia, such as age, DM, and female sex, 29 are also independent factors for the incidence of AD, supporting that our data are solid. However, antihypertensive regimens other than ARBs were not equally distributed in the 2 groups. Patients in the ARB group tended to have a higher prescription rate for α-blockers (17.6% vs. 13.0%, P<0.001), CCBs (85.5% vs. 83.5%, P<0.01) and thiazides (28.3% vs. 19.7%, P<0.001). Because raw BP data are not shown in the NHI Research Database, we could not determine the BP control conditions in each cohort. Slightly more drugs combined in the BP-lowering regimens in the ARB group might imply a more severe HT condition, needing more drugs to achieve BP control or, on the other hand, indicate better BP status after more adequate medical control through the use of more antihypertensive drugs. The hazard ratios of ARB use and risk of AD in subgroup analysis according to different antihypertensive medications are shown in Figure S1 , and no difference in AD risk was found in each subgroup of antihypertensive drugs.
Furthermore, some important confounding variables were lacking in the NHI Research Database, such as family history of stroke or dementia, educational status, body mass index, cigarette smoking habit, previous intolerance to other drug classes, and severity of comorbid diseases. We tried to get an accurate diagnosis of AD by using a detailed case selection Hazard ratios (HR) of angiotensin-receptor blocker (ARB) use and risk of Alzheimer's disease (AD) in subgroup analysis; by proportional hazards regression analysis, adjusted for age, gender, diabetes mellitus, history of coronary heart disease, arrhythmia, hyperlipidemia, and heart failure. CI, confidence interval.
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method based on a designated ICD code diagnosis, but the disease could still have been misclassified at baseline and during follow-up. Because of the limitation of the database, the prevalence of mild cognitive impairment (a transition phase between healthy cognitive aging and dementia) and the longitudinal decline in cognitive function (quantified by MMSE or other methodology) could not be assessed. In fact, our study covered only an average 5-year period, which might not be long enough to demonstrate the effect of ARBs on AD because the natural course of cognitive function decline begins from mid-life.
In conclusion, although emerging evidence suggests that the RAS may be involved in the incidence of AD, the beneficial treatment effect of RAS blockade, specifically regarding ARBs, remains unclear. Our study disclosed that the association between ARBs and the incidence of AD in Asian patients with systemic HT was not significant. Further well-designed prospective randomized trials are needed to elucidate these issues. Before further clinical evidence appears, we should continue to focus on appropriate BP control and aggressive treatment of other cardiovascular risk factors in patients with or at risk for AD.
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